Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 11:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–38 of 38 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Peripheral/Central Venous Blood Draw Clear all

Conditions: Fibromyalgia, Chronic Fatigue Syndrome, Multiple Sclerosis, Healthy
Interventions: [Zr-89]Oxine-labeled leukocytes PET/MRI; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 65 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Heart Failure
Interventions: Fentanyl, Catheters, Exercise, DEXA, Pulmonary Function Tests, Blood Draw, Chemosensitivity Test, Placebo; Drug · Procedure · Other + 1 more
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 90 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Aging
Interventions: Sham, Therapeutic Plasma Exchange, IVIG; Device · Drug
Lead sponsor: Dobri Kiprov; Industry
Eligibility: 50 Years to 95 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Mill Valley, California

Conditions: Neuroblastoma
Interventions: buthionine sulfoximine, melphalan, Peripheral blood stem cell infusion, Filgrastim; Drug · Procedure · Other
Lead sponsor: New Approaches to Neuroblastoma Therapy Consortium; Other
Eligibility: Up to 30 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2016
U.S. locations: 8
States / cities: Los Angeles, California • San Francisco, California • Chicago, Illinois + 5 more

Conditions: Anemia, Sickle Cell, Sickling Disorder Due to Hemoglobin S
Interventions: Rapid manual partial exchange transfusion, Simple Transfusion; Other
Lead sponsor: Chattanooga-Hamilton County Hospital Authority; Other
Eligibility: 3 Years to 25 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Chattanooga, Tennessee

Conditions: Neuroblastoma
Interventions: Filgrastim, Carboplatin, Etoposide, Melphalan, Peripheral blood stem cell infusion, 131I-MIBG, Radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: New Approaches to Neuroblastoma Therapy Consortium; Other
Eligibility: 1 Year to 29 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2013
U.S. locations: 14
States / cities: Los Angeles, California • Palo Alto, California • San Francisco, California + 11 more

Conditions: Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions: anti-thymocyte globulin, busulfan, cyclophosphamide, fludarabine phosphate, methotrexate, tacrolimus, nonmyeloablative allogeneic HSCT; Biological · Drug · Procedure
Lead sponsor: Northside Hospital, Inc.; Other
Eligibility: Up to 75 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Multiple Myeloma
Interventions: myPRS, Induction 1 - MEL-10+CFZ-TD-PACE, First Transplant - MEL-80+CFZ-TD-PACE + PBSC (biologic), Inter-Therapy - MEL-20+CFZ-TD-PACE (75%), Second Transplant - MEL-80+CFZ-TD-PACE + PBSC (biologic), Consolidation - CFZ-TD-PACE, Maintenance - CFZ-R(T)-D; Device · Drug
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Central Retinal, Hemi Retinal & Brach Retinal Vein Occlusions
Interventions: 0.5mg Ranibizumab, Targeted Pan Retinal Photocoagulation; Drug · Procedure
Lead sponsor: Charles C Wykoff, PhD, MD; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 3
States / cities: Houston, Texas • Katy, Texas • The Woodlands, Texas

Conditions: Multiple Myeloma
Interventions: Melphalan, Bortezomib; Drug
Lead sponsor: Hackensack Meridian Health; Other
Eligibility: 60 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2022
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Hackensack, New Jersey

Conditions: Ascites, Liver Cirrhosis, Hypertension, Portal
Interventions: Proximal Splenic Artery Embolization; Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Hemophilia A, Factor VIII Deficiency, Hemophilia, Hemophilia B, Factor IX Deficiency
Interventions: Peripheral Vein Blood draw; Procedure
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: 1 Year to 21 Years · Male only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Carcinoma, Pancreatic Ductal
Interventions: Peripheral/Central Venous Blood Draw, Peritoneal Wash; Procedure
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 85 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Lymphoma
Interventions: bevacizumab, cyclophosphamide, doxorubicin, prednisone, vincristine; Biological · Drug
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 110
States / cities: Greenbrae, California • Palo Alto, California • Fort Collins, Colorado + 77 more

Search by objective public record fields.

Tracking Peripheral Immune Cell Infiltration of the Brain in Central Inflammatory Disorders Using [Zr-89]Oxinate-4-labeled Leukocytes.

Mechanisms of Altered Ventilatory Control in Heart Failure

The Effects Of Therapeutic Plasma Exchange (TPE) On Age Related Biomarkers And Epigenetics

N99-02: Melphalan and Buthionine Sulfoximine

Comparison of Two Methods of Transfusion for Stroke Prevention in Sickle Cell

N2001-02: I-MIBG With Intensive Chemotherapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma

Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer

UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission

Widefield Angiography Guided Targeted-retinal Photocoagulation Combined With Anti VEgf Intravitreal Injections for the Treatment of Ischemic Central Retinal Vein Occlusion, Hemi Retinal Vein Occlusion, and Branch Retinal Vein Occlusion

Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older

Proximal Splenic Artery Embolization (PSAE) for the Treatment of Refractory Ascites in Decompensated Cirrhosis

A Study Comparing Factor Level and Inhibitor Titer Testing Results Drawn From Central Venous Lines and Venipuncture

Circulating Tumor Cells in Operative Blood

Bevacizumab and Combination Chemotherapy in Treating Patients With Peripheral T-Cell Lymphoma or Natural Killer Cell Neoplasms